Bolt Biotherapeutics(BOLT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC3042 in patients with advanced cancers • Presented updated preclinical activity of BDC-4182 and key learnings from Phase 1 doseescalation trial of BDC-1001 at the SITC 39th Annual Meeting • BDC-4182 on track to start clinical trials in second quarter 2025 • Cash balance of $84.4 million as of September 30, 2024 an ...